Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Promising Early Alzheimer's Data Can't Quell Efficacy Concerns

Executive Summary

The publication of Phase I analyses for Merck & Co.'s Alzheimer's therapy, verubecestat, may help to explain why the company decided to pursue costly Phase III studies without more data – but questions still remain around the drug's fundamental hypothesis that modulating the brain amyloid system will translate into a clinical response.

Advertisement

Related Content

Amgen, Novartis May Screen 30,000 Patients To Find 2,000 For Alzheimer's Trial
Alzheimer’s Update: Amyloid Hypothesis Lives On At Biogen, Lilly, Merck, Pfizer, Roche
After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
Alzheimer's Disease: Learning the Lessons Of The Past To Prepare For The Future

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097613

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel